Select Topic:
Browse by Series:

Antiangiogenic Agents in Ovarian Cancer

Panelists:Michael J. Birrer, MD, PhD, Mass General ; Robert A. Burger, MD, Fox Chase Cancer Center; Warner K. Huh, MD, UAB ; Maurie Markman, MD, CTCA ; James Tate Thigpen, MD, University of Mississippi School of Medicine
Published: Thursday, Mar 05, 2015

For High-Definition, Click
Bevacizumab is an antiangiogenic agent that exploits the tumor microvasculature, explains Robert A. Burger, MD. As long as there is no disease progression or unacceptable toxicities, and patients are willing to receive it, bevacizumab therapy should be continued indefinitely, states James Tate Thigpen, MD.

In November 2014, the FDA approved bevacizumab in combination with chemotherapy for patients with platinum-resistant recurrent ovarian cancer. The decision was based on findings from the phase III AURELIA trial, which demonstrated a median PFS with bevacizumab of 6.8 versus 3.4 months with chemotherapy alone (HR = 0.38; P <.0001). 

Burger notes that there are studies in non-gynecologic tumors, such as colon cancer, that have continued antiangiogenic therapy beyond disease progression and demonstrated survival advantage in the next line of therapy. Clinical trials evaluating the utilization of antiangiogenic agents beyond disease progression in ovarian cancer are ongoing in Europe.

Slider Left
Slider Right
For High-Definition, Click
Bevacizumab is an antiangiogenic agent that exploits the tumor microvasculature, explains Robert A. Burger, MD. As long as there is no disease progression or unacceptable toxicities, and patients are willing to receive it, bevacizumab therapy should be continued indefinitely, states James Tate Thigpen, MD.

In November 2014, the FDA approved bevacizumab in combination with chemotherapy for patients with platinum-resistant recurrent ovarian cancer. The decision was based on findings from the phase III AURELIA trial, which demonstrated a median PFS with bevacizumab of 6.8 versus 3.4 months with chemotherapy alone (HR = 0.38; P <.0001). 

Burger notes that there are studies in non-gynecologic tumors, such as colon cancer, that have continued antiangiogenic therapy beyond disease progression and demonstrated survival advantage in the next line of therapy. Clinical trials evaluating the utilization of antiangiogenic agents beyond disease progression in ovarian cancer are ongoing in Europe.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x